FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 345:1919 December 27, 2001 Number 26 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited

Edited by Julien Bogousslavsky. 303 pp. London, Taylor and Francis, 2001. $95. ISBN 0-7484-0934-3.

Two decades ago, it would have been unthinkable that the devastating effects of ischemic stroke would ever be completely reversible, but with thrombolysis this is now a reality. Unfortunately, the therapeutic window remains impracticably narrow (the three-hour barrier has not yet been effectively overcome), and the treatment is very expensive, so that even in the developed world successful thrombolysis is only possible in a tiny minority of patients.

Stroke is now the second most common cause of death globally, with most cases occurring in the developing world, according to statistics from the World Health Organization. Unlike the impracticality of treating . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.